Hanmi Pharm (128940) Stock Outlook 2026: GLP-1 Pipeline & MSD Milestones

Hanmi Pharmaceutical holds a rare distinction among Korean drug companies: it has executed licensing deals with Sanofi, Janssen, Eli Lilly, and Roche — a track record few emerging-market biotech firms can match. The engine behind every deal is Lapscovery, a platform technology that turns short-lived peptides into once-weekly or once-monthly injectables. In 2026, the question is whether the next GLP-1 wave produces a deal that resets the company’s valuation, or whether clinical execution risk materializes again.

What Lapscovery Actually Does — and Why It Matters

Lapscovery fuses peptide or protein drugs to an immunoglobulin Fc fragment. The Fc domain extends plasma half-life from minutes (natural GLP-1 degrades in under 2 minutes) to days, enabling weekly dosing regimens that rival Novo Nordisk’s semaglutide technology.

The platform is technology-agnostic across indications: GLP-1 agonists, insulin analogs, growth hormone, erythropoietin, and immune modulators can all be modified using the same core chemistry. This is why Hanmi can run multiple licensing programs simultaneously without each requiring a new technological foundation.

Why this matters for investors: When a single Lapscovery-based asset fails clinical trials, the platform itself is not invalidated. Hanmi can pivot to the next candidate. This differentiates Hanmi from single-asset biotechs where one Phase 3 failure is existential.

The GLP-1 Pipeline: Three Tiers of Development

Efpeglenatide: The Pioneer with Cardiovascular Data

Efpeglenatide is Hanmi’s most clinically mature GLP-1 asset. Its AMPLITUDE-O cardiovascular outcomes trial (results published in New England Journal of Medicine, 2021) demonstrated significant reductions in major adverse cardiovascular events — a critical hurdle for regulatory approval of GLP-1 therapies in high-risk patients.

The Sanofi partnership history is well documented: $434 million upfront in 2015, followed by the December 2016 return which triggered $250 million repayment. Post-return, Hanmi has been advancing efpeglenatide independently. Current Phase and NCT registration: verify at ClinicalTrials.gov using the drug name “efpeglenatide.”

HM12525A: GLP-1/Glucagon Dual Agonist (Janssen Deal)

HM12525A is an oxyntomodulin analogue acting on both GLP-1 and glucagon receptors. The dual mechanism theoretically delivers greater weight loss than single GLP-1 agonism while preserving liver-protective effects through the glucagon pathway.

The Janssen (Johnson & Johnson) license agreement was signed in 2015 at $105 million upfront with up to $810 million in development milestones. The current status of this program under Janssen’s control: verify via J&J pipeline disclosures and DART Hanmi filings.

Next-Generation Tri-Agonist Programs

Hanmi is developing GLP-1/GIP/glucagon triple receptor agonists — a mechanistic step beyond Eli Lilly’s tirzepatide (which is GLP-1/GIP dual). The thesis is that glucagon co-activation increases energy expenditure, improving weight loss beyond what GLP-1/GIP dual agonism achieves. Phase and status: verify via DART.

Related: Eli Lilly (LLY) Stock Outlook 2026 →

GLP-1 Competitive Landscape: Where Hanmi Fits

Drug	Company	Mechanism	Dosing	US Approval
Semaglutide	Novo Nordisk	GLP-1	Weekly/Daily	Obesity: 2021
Tirzepatide	Eli Lilly	GLP-1+GIP	Weekly	Obesity: 2023
Efpeglenatide	Hanmi	GLP-1	Weekly	Not approved (clinical)
HM12525A	Hanmi/Janssen	GLP-1+Glucagon	TBD	Clinical stage

The global GLP-1 obesity market is projected to reach hundreds of billions of dollars by the early 2030s (consensus estimates from IQVIA, Evaluate Pharma — verify latest figures). Hanmi is not in the first-mover tier (Novo/Lilly) but is positioned in the second tier that could command licensing interest from any of the dozen global pharma companies seeking GLP-1 portfolio expansion.

MSD (Merck) Licensing: Understanding Milestone Accounting

Hanmi’s revenue model is fundamentally a milestone engine rather than a commercial sales engine. This creates a distinctive earnings pattern that requires a different analytical lens.

How milestone revenue recognition works under IFRS 15:

1. Upfront (day-one): Recognized as revenue at contract execution — but only the portion not contingent on future performance.
2. Development milestones: Recognized when the performance obligation (completing a Phase 2 trial, submitting an NDA) is met.
3. Sales milestones: Recognized when partner’s cumulative sales cross a threshold.
4. Royalties: Recognized as earned on actual partner sales.

The practical implication: Hanmi’s quarterly earnings look lumpy. A milestone-heavy quarter shows a surge in revenue and operating profit; a quarter with no milestone event can show thin margins. The right metric to track is not quarterly EPS but pipeline event schedule — what milestones are due, under which contracts, in what quarter.

For MSD deal specifics, milestones due and status: DART dart.fss.or.kr → Hanmi Pharmaceutical 128940 → Material Event Report (주요사항보고서).

IFRS R&D Capitalization: The Hidden Earnings Quality Issue

Under IFRS IAS 38, development costs meeting six specific criteria can be capitalized (booked as an intangible asset on the balance sheet) rather than expensed immediately. Hanmi applies this standard.

The consequence: During active development, operating margins appear better than cash-based economics would suggest. When a trial fails or an asset is returned, the capitalized amount must be written down — often creating a large impairment charge in a single quarter.

What to check in DART filings:

• Note on “Intangible Assets” (무형자산) — total capitalized R&D balance
• Note on “Research and Development Costs” (연구개발비) — split between capitalized and expensed
• Impairment testing disclosures

The Sanofi return in 2016 resulted in impairment charges that contributed to a dramatic single-quarter loss. Any investor in Hanmi must understand and size this risk for current pipeline assets.

Peer Comparison: Hanmi vs Celltrion vs Yuhan

Metric	Hanmi (128940)	Celltrion (068270)	Yuhan (000100)
Core strategy	License-out (GLP-1/metabolic)	Biosimilar direct commercialization	Lazertinib (Rybrevant) BLA
Platform	Lapscovery	Biosimilar CMC	Small molecule oncology
Key partners	Sanofi·Janssen·MSD	Self (EU/US direct)	J&J (JNJ)
Revenue model	Upfront + milestones + royalties	Product sales	License-out + domestic
R&D intensity	High (with capitalization)	High (expense-heavy)	Moderate

For current P/E, P/B, operating margin, and R&D-to-revenue ratios: access DART filings directly. These figures change quarterly and cannot be reliably stated from training data.

Related: Samsung Biologics (207940) Outlook 2026 →

Regulatory Framework: MFDS and FDA Pathways

For Hanmi’s GLP-1 assets:

• US FDA NDA/NME review: New chemical entities require full FDA review. GLP-1 receptor agonists are small molecules (or in efpeglenatide’s case, a peptide-Fc fusion requiring biological NDA or NME designation — confirm with actual regulatory submissions).
• Korean MFDS approval: Domestic approval may be sought separately or in parallel with FDA. Korean health insurance (NHIS) formulary listing determines domestic commercial value.
• EMA (Europe): European approval through centralized procedure at the EMA.

IRA implications: Medicare drug price negotiation targets products with high cumulative US Medicare spend. Hanmi’s GLP-1 assets are not yet on the US market, so IRA impacts Hanmi through partners’ US strategies rather than directly.

Risk Map

Clinical execution risk is the primary risk for Hanmi. Three specific scenarios to model:

1. Phase 3 failure: Operating loss in the quarter of disclosure due to capitalized R&D impairment + no future milestone revenue from that asset.
2. Asset return by partner: Historical precedent (Sanofi 2016) shows >30% single-day stock decline risk.
3. Data underwhelms vs semaglutide/tirzepatide: Even with approval, if efficacy data don’t differentiate, partner commercialization may be slow — delaying sales milestones and royalties.

Non-clinical risks:

• KRW/USD forex: Milestones denominated in USD translate at prevailing exchange rate
• Korean biotech sector sentiment: KOSPI biotech index correction can drag Hanmi regardless of pipeline news
• MSCI Korea rebalancing: Institutional flow changes based on index weighting adjustments

Bull vs. Bear Scenarios

Bull case — what to watch:

• Efpeglenatide or HM-series Phase 3 data showing ≥15% mean body weight reduction (competitive with tirzepatide range)
• Additional MSD milestone recognition in quarterly earnings
• New global licensing deal (upfront payment announcement)
• US obesity drug market expansion via insurance coverage mandates

Bear case — what to watch:

• Clinical trial failure or FDA Complete Response Letter
• R&D impairment charge in quarterly earnings
• Partner returns asset citing internal pipeline prioritization
• Competing molecules (Amgen, Pfizer, AZ next-gen GLP-1) show superior data, reducing acquisition interest in Hanmi’s platform

How to Access and Trade Hanmi Stock

Hanmi Pharmaceutical trades on the KOSPI under ticker 128940. For global investors:

• Direct access: Korean market account via Interactive Brokers, Schwab International, or Korean brokers accepting foreign clients
• Indirect exposure: iShares MSCI South Korea ETF (EWY) or similar — Hanmi is a KOSPI constituent but weighting varies
• No ADR available: There is no US-listed ADR for 128940

For real-time pipeline news: DART filing alerts (dart.fss.or.kr), Korean financial media (한국경제, 매일경제), Korea Biomed News.

GLP-1 Market Dynamics: Why the Window Matters

The GLP-1 obesity market is expanding faster than most pharmaceutical precedents. Novo Nordisk’s Wegovy faced a supply shortage immediately after launch — a demand signal that surprised even the company. Eli Lilly’s Zepbound (tirzepatide) launch in late 2023 sold out quickly. Both companies are building manufacturing capacity at a pace not seen since COVID vaccine production.

For Hanmi, the window of opportunity has specific characteristics:

The partnership opportunity: Big pharma companies that do not yet have an approved GLP-1 obesity drug are actively scouting pipeline-stage assets for in-licensing. The list includes AstraZeneca, Pfizer (after danuglipron oral setbacks), Bristol Myers Squibb, Novartis, and several others. Hanmi’s Lapscovery-modified candidates fit exactly the profile these companies seek: differentiated mechanism (dual/triple agonist), weekly dosing, and clinical proof of concept.

The clinical differentiation requirement: Being a GLP-1 agonist is no longer sufficient. The market now expects candidates to show mean body weight reduction in Phase 3 that competes with tirzepatide’s roughly 20–22% at maximum dose. Hanmi must demonstrate its candidates can reach this bar or target a specific sub-population (non-responders to semaglutide, patients with NASH/fatty liver, etc.) to carve out a defensible commercial position.

The timeline pressure: Global pharma licensing interest is highest when clinical data are fresh and Phase 3 is either ongoing or recently completed. If Hanmi’s Phase 3 data emerge in 2026–2027, this is the maximum licensing-interest window. Delays push Hanmi into an increasingly crowded field.

Korean Biotech Sector Context: KOSPI Biotech Index Dynamics

Korean biotech stocks trade with high correlation to each other and to global biotech sentiment. Understanding this context matters for position sizing and entry timing.

Key sector dynamics:

• KOSPI Healthcare Index: When US biotech (XBI, IBB) corrects, Korean biotech follows with amplified volatility. This is a beta-to-global-biotech risk, not just idiosyncratic company risk.
• Retail investor-driven volatility: Korean retail investors (“개미”) account for a disproportionately large share of KOSPI volume. Pipeline news events can trigger momentum moves that overshoot fundamentals in both directions.
• Short-selling regime: Korea has periodically restricted short-selling on KOSPI stocks, which affects the ability of institutional investors to hedge biotech positions. Current short-selling rules: verify via KRX.
• MSCI Korea rebalancing: Semi-annual MSCI index reviews can cause institutional buying or selling unrelated to Hanmi’s fundamentals.

The practical implication: Hanmi’s stock price will reflect both company-specific pipeline news and broader KOSPI biotech sentiment. Global biotech ETF positioning is a useful cross-check for Korean biotech sector timing.

Korean Pharma Policy: NHIS and Drug Pricing

South Korea’s National Health Insurance Service (NHIS) is the single-payer that determines domestic drug pricing. For any GLP-1 obesity drug that Hanmi eventually brings to the Korean market, NHIS coverage status determines actual commercial scale.

NHIS drug pricing framework:

• New drugs are reviewed by the Health Insurance Review and Assessment Service (HIRA)
• Pricing negotiation between NHIS and manufacturers is based on comparative effectiveness and cost-effectiveness analysis
• Obesity drugs face additional scrutiny because obesity is classified as a “lifestyle disease” in Korea — coverage may require stricter medical criteria than in the US

For imported GLP-1 drugs (Wegovy, Zepbound) and domestically developed equivalents, NHIS listing is the inflection point from clinical approval to commercial revenue.

Tax Implications: Korean Withholding and Capital Gains for Foreign Investors

For non-resident foreign investors holding Hanmi Pharmaceutical shares:

Dividends: Korea imposes a 22% standard withholding tax on dividends paid to non-residents. Under the Korea-US tax treaty, this is reduced to 15% for US residents. Similar reductions apply under Korea’s treaties with major OECD countries. For investors in countries without a Korean tax treaty, the full 22% applies.

Capital gains: Gains on listed Korean stocks (KOSPI/KOSDAQ) held by non-resident foreign investors are generally exempt from Korean capital gains tax under Korean law. However, specific exemption conditions apply, and investors should confirm treaty status with a qualified tax advisor.

FX risk: All Korean stock transactions occur in KRW. USD/KRW, EUR/KRW, and other exchange rate movements create currency return variance separate from stock price performance.

What to Monitor Weekly: A Practical Checklist

For active investors tracking Hanmi Pharmaceutical:

Monthly/Quarterly:

• DART quarterly earnings release (분기보고서) — revenue, operating profit, R&D capitalization balance
• DART material event reports (주요사항보고서) — license deals, milestone payments, clinical trial results
• ClinicalTrials.gov — status changes on efpeglenatide and HM-series NCT numbers

Event-driven:

• Clinical trial data presentations (EASD, ADA, ENDO, obesity-specific conferences)
• FDA/MFDS IND filing approvals enabling next-phase trials
• Partner company (MSD, Janssen) pipeline update presentations — look for any mention of Hanmi assets

Macro:

• US biotech index (XBI) direction — leading indicator for Korean biotech sentiment
• Korea-specific: KOSPI Healthcare Index, retail investor buy/sell imbalance data from KRX

Lapscovery vs. Competing Half-Life Extension Platforms

Hanmi’s platform is not unique in concept — multiple pharmaceutical companies have developed Fc-fusion or albumin-fusion technologies for half-life extension. Understanding the competitive differentiation matters:

Hanmi Lapscovery: Fc-fusion using a hybrid Fc engineered to maximize half-life without triggering effector functions (ADCC, CDC). The Fc fragment is linked via a non-cleavable linker. This design allows weekly dosing for GLP-1RA and once-monthly dosing for longer-acting candidates.

Alteogen’s ALT-B4: A different approach using human albumin as the carrier domain, also targeting half-life extension for injectables. Alteogen has its own licensing track record (Halozyme HyFac royalty-bearing license was a separate story). The two Korean platform technologies target overlapping applications but use different molecular scaffolding.

Amgen’s XENCOR Fc engineering: US biotechs have developed proprietary Fc engineering for antibody optimization. The difference from Lapscovery is scale and application domain — Hanmi focuses on metabolic peptides; Amgen/Xencor focus on antibodies and cancer biologics.

The key Lapscovery advantage over competitors is the clinical-stage proof base: efpeglenatide’s AMPLITUDE-O cardiovascular outcomes study is peer-reviewed clinical evidence in the New England Journal of Medicine, establishing that the platform produces molecules with genuine therapeutic activity. This is not a preclinical promise — it is a validated clinical asset.

Scenario Analysis: Milestones That Move the Stock

Understanding which specific events will cause material stock price movement helps investors plan entry and exit timing:

High-impact events (potential ±30% single-day move):

• Phase 3 primary endpoint result: success (positive)/failure (negative)
• Major global licensing deal announcement with large upfront payment
• Partner returns asset (historical precedent: Sanofi 2016 → -30%+ in one session)
• FDA Complete Response Letter or approval

Medium-impact events (potential ±10–20% move):

• Phase 2 data presentation at major conference showing statistically significant weight loss
• Additional MSD milestone recognition in earnings surprise
• Competitor Phase 3 failure that reduces market competition for Hanmi’s assets

Low-impact events (potential ±5% move):

• DART quarterly earnings in line with consensus (no pipeline event)
• Analyst rating changes (buy/sell/hold at major Korean broker)
• MSCI Korea index weighting adjustments

Understanding this hierarchy helps investors avoid over-reacting to low-impact events and ensures appropriate position sizing for high-impact event risk.

The Long Game: Royalties as the Terminal Value Driver

Hanmi’s upfront and milestone payments generate near-term revenue spikes, but the real terminal value driver is royalty revenue — the percentage of partner sales Hanmi receives indefinitely once a drug is commercially launched.

GLP-1 royalty rates in pharma licensing typically range from 3–8% of net sales for later-stage assets. If a Hanmi-licensed GLP-1 drug reaches blockbuster status ($1B+ annual sales), even a 5% royalty yields $50M+ annually — a perpetuity that would justify a substantial portion of Hanmi’s current market capitalization on its own.

The key uncertainty: This royalty scenario is many years away and depends on clinical success, regulatory approval, commercial launch, and market penetration by the partner. But it is the reason why global pharma companies value Hanmi’s platform-based licensing model — the royalty tail is potentially very long if any candidate succeeds.

Related: Alteogen (196170) Stock Outlook 2026 →

Adjacent Pipeline: Beyond GLP-1

While GLP-1 commands attention, Hanmi’s pipeline extends beyond metabolic disease. Understanding the full breadth of active programs matters because additional licensing deals from non-GLP-1 programs can provide revenue independent of obesity drug timelines.

Oncology (EGFR/Poziotinib): Hanmi developed poziotinib (HM781-36B), a pan-HER tyrosine kinase inhibitor. The asset was licensed to Spectrum Pharmaceuticals in the US for development in NSCLC (non-small cell lung cancer) with EGFR/HER exon 20 insertions. The US FDA granted Breakthrough Therapy Designation (BTD) for this indication at one point. Current status: verify via FDA database and Spectrum Pharmaceuticals IR.

Long-Acting Insulin (LAPSInsulin): Lapscovery-modified insulin formulations are part of Hanmi’s diabetes franchise. Weekly or monthly insulin could address medication adherence gaps in diabetes management — a different commercial angle from the GLP-1 space but complementary in a metabolic disease portfolio.

GLP-1/GIP/Glucagon Triple (HM15275): This program aims to deliver greater weight loss than tirzepatide (GLP-1/GIP dual) by adding glucagon receptor agonism. Glucagon activation increases hepatic glucose output and energy expenditure — potentially providing additive weight loss on top of GLP-1-driven satiety. The clinical stage of HM15275: verify via DART and ClinicalTrials.gov.

Long-Acting Growth Hormone (LAPS-GH): A weekly growth hormone replacement therapy using Lapscovery. The growth hormone replacement market is smaller than GLP-1 but has reliable reimbursement in pediatric and adult GHD indications.

AMPLITUDE-O: What the Published Data Tells Us

The AMPLITUDE-O trial is the most important published clinical dataset for Hanmi’s GLP-1 program. The results, published in New England Journal of Medicine in 2021, enrolled patients with type 2 diabetes at high cardiovascular risk who had not previously received injectable therapy.

Key findings (published data, freely available):

• Efpeglenatide significantly reduced the risk of major adverse cardiovascular events (MACE) vs placebo
• Significant weight reduction was observed across dose groups
• GI tolerability profile was consistent with the GLP-1 class

The AMPLITUDE-O data matter for two reasons: First, they validate efpeglenatide as a functional GLP-1RA with cardiovascular outcomes benefit — not merely a “me-too” in vitro compound. Second, cardiovascular outcomes data are increasingly required or expected for GLP-1 approvals in high-risk patient populations (diabetic, obese with CVD history).

Poziotinib in Context: What the Oncology Pipeline Means

Understanding Hanmi’s oncology program matters because it represents a non-correlated revenue opportunity — a Phase 2/3 success in NSCLC is independent of whether any GLP-1 program advances.

Poziotinib targets EGFR/HER exon 20 insertion mutations — a subset of NSCLC patients (approximately 2–3% of NSCLC cases) who historically responded poorly to first-generation EGFR inhibitors. Amivantamab (Rybrevant, from J&J) subsequently won FDA accelerated approval for this indication. The competitive landscape now includes multiple agents.

For Hanmi, the Spectrum Pharmaceuticals licensing deal means milestone and royalty potential if poziotinib achieves regulatory approval. The financial contribution is smaller than a GLP-1 blockbuster scenario, but represents portfolio diversification — not all of Hanmi’s value is at risk if GLP-1 programs stumble. From a portfolio construction standpoint, an oncology program that advances independently of the metabolic disease cycle provides meaningful variance reduction in Hanmi’s overall earnings trajectory.

Operating Leverage in the Milestone Revenue Model

Hanmi’s cost structure provides operating leverage in favorable milestone years:

The company maintains a relatively fixed R&D and overhead cost base (partially offset by R&D capitalization). When a large milestone is recognized — for instance, a $100M+ payment from MSD or a new partner — nearly all of it flows through to operating income because no incremental costs are incurred to “earn” the milestone (the clinical work was already done).

This means a single large milestone year can produce operating margins of 30–50%+ — dramatically higher than typical pharma operating margins. The risk is the mirror image: years without milestones show thin or negative operating margins if R&D capitalization is insufficient to offset expenses.

Understanding this dynamic helps explain why Hanmi is not a “smooth compounder” but rather a lumpy binary-event stock best analyzed by pipeline calendar rather than EPS trend.

Official sources:

• DART: dart.fss.or.kr
• Hanmi IR: hanmipharm.com
• ClinicalTrials.gov: efpeglenatide NCT search
• MFDS: mfds.go.kr
• KRX: krx.co.kr

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All investment decisions are made at the reader’s own risk and after independent due diligence.